CC-5013 in Treating Patients With Recurrent Glioma

NCT00036894 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: lenalidomide

Sponsor

National Cancer Institute (NCI)